In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

A new alert from the FDA warns that some sensors from Abbott may give incorrect blood sugar readings, which could lead to unsafe treatment decisions.

About 3 million glucose monitoring sensors were potentially affected by a production error that caused incorrect low glucose ...

Global healthcare giant Abbott is recalling faulty blood glucose sensors across multiple countries due to potentially ...

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, ...

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 14.8% in the afternoon session after the company reported underwhelming earnings. The company's revenue grew over 21% year-on-year to $1.21 ...

Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...

A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device. Some patients reportedly experienced severe ...

This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.

Tire pressure monitoring sensors (TPMS) work by constantly measuring the air pressure within all four of your tires, then relaying that data to your car's computer. If the system is unable to measure ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...